NASDAQ:IOVA Iovance Biotherapeutics (IOVA) Stock Forecast, Price & News $8.80 +0.07 (+0.80%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$8.66▼$9.0050-Day Range$5.36▼$9.0652-Week Range$5.28▼$13.44Volume4.96 million shsAverage Volume4.52 million shsMarket Capitalization$1.98 billionP/E RatioN/ADividend YieldN/APrice Target$19.09 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Iovance Biotherapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside116.9% Upside$19.09 Price TargetShort InterestBearish12.86% of Float Sold ShortDividend StrengthN/ASustainability-0.53Upright™ Environmental ScoreNews Sentiment0.42Based on 26 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.39) to ($1.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector296th out of 983 stocksBiological Products, Except Diagnostic Industry42nd out of 164 stocks 3.4 Analyst's Opinion Consensus RatingIovance Biotherapeutics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 8 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.09, Iovance Biotherapeutics has a forecasted upside of 116.9% from its current price of $8.80.Amount of Analyst CoverageIovance Biotherapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted12.86% of the float of Iovance Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverIovance Biotherapeutics has a short interest ratio ("days to cover") of 5.9.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldIovance Biotherapeutics does not currently pay a dividend.Dividend GrowthIovance Biotherapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIovance Biotherapeutics has received a 75.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" product. See details.Environmental SustainabilityThe Environmental Impact score for Iovance Biotherapeutics is -0.53. Previous Next 3.0 News and Social Media Coverage News SentimentIovance Biotherapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for Iovance Biotherapeutics this week, compared to 3 articles on an average week.Search Interest43 people have searched for IOVA on MarketBeat in the last 30 days. This is an increase of 258% compared to the previous 30 days.MarketBeat Follows10 people have added Iovance Biotherapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Iovance Biotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders10.40% of the stock of Iovance Biotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.78% of the stock of Iovance Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Iovance Biotherapeutics are expected to grow in the coming year, from ($2.39) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Iovance Biotherapeutics is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Iovance Biotherapeutics is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIovance Biotherapeutics has a P/B Ratio of 2.96. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Iovance Biotherapeutics (NASDAQ:IOVA) StockIovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.Read More Receive IOVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Iovance Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address IOVA Stock News HeadlinesMay 30, 2023 | marketbeat.com Iovance Biotherapeutics Spikes on Melanoma BLA FDA Application Iovance Biotherapeutics Inc. (NASDAQ: IOVA) shares spiked over 20% on its advanced-stage melanoma treatment application to the U.S. Food and Drug AdminJune 1, 2023 | americanbankingnews.comWells Fargo & Company Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to "Overweight"June 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.June 1, 2023 | americanbankingnews.comStifel Nicolaus Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $24.00May 31, 2023 | seekingalpha.comIovance: Hard To Resist This Historic Solid Tumor Cell Therapy Approval ShotMay 30, 2023 | nasdaq.comHC Wainwright & Co. Reiterates Iovance Biotherapeutics (IOVA) Buy RecommendationMay 30, 2023 | msn.comChardan Capital Reiterates Iovance Biotherapeutics (IOVA) Buy RecommendationMay 30, 2023 | finance.yahoo.comThese Stocks Moved the Most Today: Nvidia, Marvell, C3.ai, Palantir, and MoreJune 3, 2023 | Legacy Research (Affiliate) (Ad)“One-Stock Millionaire” IGNORES 99.9% of the MarketDuring the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.May 30, 2023 | finance.yahoo.comWhy Shares of Iovance Biotherapeutics Jumped TuesdayMay 30, 2023 | proactiveinvestors.comIovance Biotherapeutics shares rally on receiving FDA priority review for melanoma drugMay 30, 2023 | markets.businessinsider.comWhat's Going On With Iovance Biotherapeutics Stock?May 30, 2023 | msn.comIovance rises as Wall Street reacts to FDA priority review for melanoma drugMay 30, 2023 | msn.comJMP Securities Reiterates Iovance Biotherapeutics (IOVA) Market Perform RecommendationMay 30, 2023 | markets.businessinsider.comWhere Iovance Biotherapeutics Stands With AnalystsMay 30, 2023 | msn.comIovance Surges after U.S. FDA Approval for LifileucelMay 30, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)May 30, 2023 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on Iovance Biotherapeutics (IOVA)May 30, 2023 | markets.businessinsider.comJMP Securities Remains a Buy on Iovance Biotherapeutics (IOVA)May 29, 2023 | markets.businessinsider.comIovance Biotherapeutics (IOVA) Gets a Hold from Goldman SachsMay 28, 2023 | americanbankingnews.comEquities Analysts Issue Forecasts for Iovance Biotherapeutics, Inc.'s Q2 2023 Earnings (NASDAQ:IOVA)May 27, 2023 | americanbankingnews.comTraders Buy Large Volume of Call Options on Iovance Biotherapeutics (NASDAQ:IOVA)May 26, 2023 | marketwatch.comIovance Shares Shares Get After-Hours Boost From FDA ApprovalMay 26, 2023 | msn.comCramer's Lightning Round: Vornado is a buyMay 26, 2023 | americanbankingnews.comIovance Biotherapeutics (NASDAQ:IOVA) Trading Down 6%May 25, 2023 | americanbankingnews.comRobert W. Baird Increases Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $23.00May 24, 2023 | benzinga.comIovance Biotherapeutics shares are trading lower on profit taking after the stock rallied yesterday.See More Headlines IOVA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IOVA Company Calendar Last Earnings5/09/2023Today6/02/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:IOVA CUSIPN/A CIK1425205 Webwww.iovance.com Phone(650) 260-7120FaxN/AEmployees319Year Founded2013Price Target and Rating Average Stock Price Forecast$19.09 High Stock Price Forecast$38.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+116.9%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-395,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.00% Return on Assets-62.24% Debt Debt-to-Equity RatioN/A Current Ratio7.31 Quick Ratio7.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.97 per share Price / Book2.96Miscellaneous Outstanding Shares224,450,000Free Float201,106,000Market Cap$1.98 billion OptionableOptionable Beta0.18 Social Links Key ExecutivesFrederick G. VogtPresident, CEO, Secretary & General CounselIgor P. BilinskyChief Operating OfficerJean-Marc BelleminCFO & Principal Accounting OfficerFriedrich Graf FinckensteinChief Medical OfficerBrian ShewSVP & Head-Information TechnologyKey CompetitorsArcellxNASDAQ:ACLXSpringWorks TherapeuticsNASDAQ:SWTXRecursion PharmaceuticalsNASDAQ:RXRXKymera TherapeuticsNASDAQ:KYMRImmunocoreNASDAQ:IMCRView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 46,435 shares on 6/1/2023Ownership: 0.021%Ameriprise Financial Inc.Sold 1,168,247 shares on 5/22/2023Ownership: 0.064%JPMorgan Chase & Co.Sold 266,749 shares on 5/18/2023Ownership: 0.922%New York State Common Retirement FundBought 85,786 shares on 5/18/2023Ownership: 0.302%Rockefeller Capital Management L.P.Bought 2,000 shares on 5/17/2023Ownership: 0.016%View All Insider TransactionsView All Institutional Transactions IOVA Stock - Frequently Asked Questions Should I buy or sell Iovance Biotherapeutics stock right now? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IOVA shares. View IOVA analyst ratings or view top-rated stocks. What is Iovance Biotherapeutics' stock price forecast for 2023? 11 analysts have issued 12 month price targets for Iovance Biotherapeutics' stock. Their IOVA share price forecasts range from $6.00 to $38.00. On average, they predict the company's stock price to reach $19.09 in the next year. This suggests a possible upside of 116.9% from the stock's current price. View analysts price targets for IOVA or view top-rated stocks among Wall Street analysts. How have IOVA shares performed in 2023? Iovance Biotherapeutics' stock was trading at $6.39 at the start of the year. Since then, IOVA shares have increased by 37.7% and is now trading at $8.80. View the best growth stocks for 2023 here. When is Iovance Biotherapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our IOVA earnings forecast. How were Iovance Biotherapeutics' earnings last quarter? Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) issued its quarterly earnings data on Tuesday, May, 9th. The biotechnology company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.84) by $0.34. During the same quarter last year, the business posted ($0.58) EPS. What ETFs hold Iovance Biotherapeutics' stock? ETFs with the largest weight of Iovance Biotherapeutics (NASDAQ:IOVA) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Harbor Disruptive Innovation ETF (INNO), Principal Healthcare Innovators ETF (BTEC) and ARK Genomic Revolution ETF (ARKG). What other stocks do shareholders of Iovance Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Kadmon (KDMN), Immunomedics (IMMU), Bristol-Myers Squibb (BMY), Seagen (SGEN), CA (CA), Advanced Micro Devices (AMD), BlackRock (BLK) and Novavax (NVAX). What is Iovance Biotherapeutics' stock symbol? Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA." Who are Iovance Biotherapeutics' major shareholders? Iovance Biotherapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (6.83%), State Street Corp (6.12%), BlackRock Inc. (5.55%), Price T Rowe Associates Inc. MD (1.67%), Boxer Capital LLC (1.65%) and Artisan Partners Limited Partnership (1.59%). Insiders that own company stock include Frederick G Vogt, Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends. How do I buy shares of Iovance Biotherapeutics? Shares of IOVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Iovance Biotherapeutics' stock price today? One share of IOVA stock can currently be purchased for approximately $8.80. How much money does Iovance Biotherapeutics make? Iovance Biotherapeutics (NASDAQ:IOVA) has a market capitalization of $1.98 billion. The biotechnology company earns $-395,890,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. How many employees does Iovance Biotherapeutics have? The company employs 319 workers across the globe. How can I contact Iovance Biotherapeutics? Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The official website for the company is www.iovance.com. The biotechnology company can be reached via phone at (650) 260-7120 or via email at achang@troutgroup.com. This page (NASDAQ:IOVA) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Iovance Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.